|Other Names||Serine/threonine-protein kinase tousled-like 1, PKU-beta, Tousled-like kinase 1, TLK1, KIAA0137|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP8101b was selected from the C-term region of human TLK1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Rapidly and transiently inhibited by phosphorylation following the generation of DNA double-stranded breaks during S- phase. This is cell cycle checkpoint and ATM-pathway dependent and appears to regulate processes involved in chromatin assembly. Isoform 3 phosphorylates and enhances the stability of the t-SNARE SNAP23, augmenting its assembly with syntaxin. Isoform 3 protects the cells from the ionizing radiation by facilitating the repair of DSBs. In vitro, phosphorylates histone H3 at 'Ser-10'.|
|Tissue Location||Widely expressed. Present in fetal placenta, liver, kidney and pancreas but not heart or skeletal muscle. Also found in adult cell lines. Isoform 3 is ubiquitously expressed in all tissues examined.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The Tousled-like kinases, first described in Arabadopsis, are nuclear serine/threonine kinases that are potentially involved in the regulation of chromatin assembly.[supplied by OMIM]
Krause, D.R., et al., Oncogene 22(38):5927-5937 (2003).Cabaniols, J.P., et al., Mol. Biol. Cell 10(12):4033-4041 (1999).Sillje, H.H., et al., EMBO J. 18(20):5691-5702 (1999).Yamakawa, A., et al., Gene 202 (1-2), 193-201 (1997).
If you have any additional inquiries please email technical services at email@example.com.